Baraclude (entecavir) Therapy Resulted in Undetectable Levels of,Hepatitis B Virus in Cohort of Patients Who Re-Started Treatment ( E is right for her. A womanshould not ...)

HOME >> MEDICINE >> TECHNOLOGY

Baraclude (entecavir) Therapy Resulted in Undetectable Levels of,Hepatitis B Virus in Cohort of Patients Who Re-Started Treatment

E is right for her. A woman should not breastfeed if she is taking BARACLUDE.

People should discuss with their healthcare provider all prescription and non-prescription medicines, vitamins, herbal supplements, and other health preparations they are taking or plan to take. BARACLUDE(R) (entecavir) may interact with medicines that leave the body through the kidneys. The most common side effects of BARACLUDE in clinical studies were headache, tiredness, dizziness, and nausea.

This list of side effects is not complete at this time because BARACLUDE is still under study. People should report any new or continuing symptom to their healthcare provider. BARACLUDE should be taken once daily on an empty stomach (at least two hours after a meal and two hours before the next meal). To learn more about BARACLUDE and for Full Prescribing Information, including boxed WARNINGS, please visit http://www.bms.com.

Bristol-Myers Squibb is a global pharmaceutical and related health care products company whose mission is to extend and enhance human life.

BARACLUDE(R) (entecavir) is a trademark of Bristol-Myers Squibb Company.

Full prescribing information for BARACLUDE, including boxed WARNINGS, is available at http://www.bms.com.

CONTACT: Media, Sonia Choi, Corporate Communications, +1-609-252-5132,, or Investors, John Elicker, Investor Relations,+1-212-546-3775, , both of Bristol-Myers Squibb sonia.choi@bms.com john.elicker@bms.com

Web site: http://www.bms.com/

Ticker Symbol: (NYSE:BMY)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

Page: 1 2 3 4 5
Related medicine technology :

1. Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load Reduction Compared to Adefovir at 48 Weeks in Study of Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients
2. Gene Chips to Detect CYP Variations: A New Step Toward Customized Medical Therapy.
3. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
4. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
5. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
6. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
7. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
8. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
9. Studies of Drug Resistance May Lead to Individual Therapy for Rare Cancers
10. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
11. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients

Post Your Comments:

(Date:12/1/2009)...Dec. 1 Reportlinker.com announces ...its catalogue: ,, Direct to Consumer (DTC) Adv...arket Outlook, Regulatory Landscape and Case Studi...rect-to-Consumer-DTC-Advertising-in-Pharmaceutical...andscape-and-Case-Studies.html ,, Summary ,...

(Date:12/1/2009)..., Dec. 1 CeloNova BioSciences, Inc...medical devices and of specialty implants, today a...r, Thomas A. Gordy, will give an opening address f...diovascular Interventions Conference in Tel Aviv, ...rest behind and focus the rich intellectual resour...

(Date:12/1/2009)... Tenn., Dec. 1 Cumberlan...today that an independently conducted study of Ace...s N-acetylcysteine, as a cost-saving treatment for...2, Number 4 of the peer-reviewed Journal of Medic...y concludes that Acetadote is a less costly treatm...

Breaking Medicine Technology:Reportlinker Adds Direct to Consumer (DTC) Advertising in Pharmaceuticals - Current and Future Market Outlook, Regulatory Landscape and Case Studies 2 Reportlinker Adds Direct to Consumer (DTC) Advertising in Pharmaceuticals - Current and Future Market Outlook, Regulatory Landscape and Case Studies 3 Reportlinker Adds Direct to Consumer (DTC) Advertising in Pharmaceuticals - Current and Future Market Outlook, Regulatory Landscape and Case Studies 4 Reportlinker Adds Direct to Consumer (DTC) Advertising in Pharmaceuticals - Current and Future Market Outlook, Regulatory Landscape and Case Studies 5 Reportlinker Adds Direct to Consumer (DTC) Advertising in Pharmaceuticals - Current and Future Market Outlook, Regulatory Landscape and Case Studies 6 Reportlinker Adds Direct to Consumer (DTC) Advertising in Pharmaceuticals - Current and Future Market Outlook, Regulatory Landscape and Case Studies 7 Reportlinker Adds Direct to Consumer (DTC) Advertising in Pharmaceuticals - Current and Future Market Outlook, Regulatory Landscape and Case Studies 8 CeloNova BioSciences CEO Urges More Heart, More Passion, More Honesty, and All Urgency in Developing Medical Devices 2 Newly Published Acetadote(R) Data Shows Product Can Provide Substantial Cost-Savings for Healthcare Systems 2 Newly Published Acetadote(R) Data Shows Product Can Provide Substantial Cost-Savings for Healthcare Systems 3 Newly Published Acetadote(R) Data Shows Product Can Provide Substantial Cost-Savings for Healthcare Systems 4 Newly Published Acetadote(R) Data Shows Product Can Provide Substantial Cost-Savings for Healthcare Systems 5 Newly Published Acetadote(R) Data Shows Product Can Provide Substantial Cost-Savings for Healthcare Systems 6 Super sleepers could help super sizers 21 9034 1 Super sleepers could help super sizers 21 9034 2 Reading the brain without poking it 9033 1 Reading the brain without poking it 9033 2 Reading the brain without poking it 9033 3 Reading the brain without poking it 9033 4 Reading the brain without poking it 9033 5 GP bodies support guidelines for use of patient records in medical research 50226 1 GP bodies support guidelines for use of patient records in medical research 50226 2

[0] Reportlinker Adds Direct to Consumer (DTC) Advertising in Pharmaceuticals - Current and Future Market Outlook, Regulatory Landscape and Case Studies [0] CeloNova BioSciences CEO Urges More Heart, More Passion, More Honesty, and All Urgency in Developing Medical Devices [0] Newly Published Acetadote(R) Data Shows Product Can Provide Substantial Cost-Savings for Healthcare Systems

...v. 7 Data from an investigational,open-label, ran...f,PROCRIT(R) (Epoetin alfa) in treating anemia in ...(CKD) were presented today at the American Society...sing groups, including the FDA-approved,three-time...d,once-every-two-weeks (Q2W) investigational regim...

...ov. 7 Spherix Incorporated,(Nasdaq: SPEX ) repor...cal,trial of its potential type 2 diabetes drug, N...India are to provide more than 300 patients spread...ow that enrollment efforts,are underway in India, ...d,on schedule as reported during the May 2008 Annu...

Other Medicine Technology:Data From Investigational Use of PROCRIT(R) (Epoetin alfa) Presented at American Society of Nephrology Annual Meeting 2 Data From Investigational Use of PROCRIT(R) (Epoetin alfa) Presented at American Society of Nephrology Annual Meeting 3 Data From Investigational Use of PROCRIT(R) (Epoetin alfa) Presented at American Society of Nephrology Annual Meeting 4 Data From Investigational Use of PROCRIT(R) (Epoetin alfa) Presented at American Society of Nephrology Annual Meeting 5 Data From Investigational Use of PROCRIT(R) (Epoetin alfa) Presented at American Society of Nephrology Annual Meeting 6 Patient Recruitment Begins in India for Phase 3 Diabetes Trial 2

Data From Investigational Use of PROCRIT(R) (Epoetin alfa) Presented at American Society of Nephrology Annual Meeting Patient Recruitment Begins in India for Phase 3 Diabetes Trial

(Date:12/1/2009).... 1 The Kerlan Jobe Ort...ngeles, has agreed to pay the United States $3 mil...l kickbacks from HealthSouth Corporation, the Just...tlement resolves allegations that HealthSouth paid...ion grants, donations to the Kerlan Jobe Foundatio...

(Date:12/1/2009)...ec. 1 A decision issued today by a... Board (NLRB) has put at risk the guaranteed raise...manente RNs, social workers, and professionals in ...rs to achieve standards at Kaiser that give us sec...e our patients need," said Jeanette Cryer, License...

(Date:12/1/2009)...gests that criteria based on computed tomography (...iver metastases after chemotherapy with the drug b...ll survival, according to a study in the December ...b to cytotoxic (toxic to cells) chemotherapy is as...tage IV colorectal cancer and higher pathologic re...

(Date:12/1/2009)...NS, Dec. 1 The American...High School Student Symposium at the New Orleans M... The symposium, which encourages an interest in he...earch, is held in conjunction with the Society,s 5...the opportunity to explore research on sickle cell...

(Date:12/1/2009)...Dec. 1 The government of Mexico Ci...ter for biomedical and nanomedical research, calle...search and development will be integrated with the... Spanish speaking university in the world. The re... 2010, has been designed by the internationally-ac...

Breaking Medicine News(10 mins):Health News:Los Angeles' Kerlan Jobe Orthopaedic Clinic Pays $3 Million to Settle Kickback Allegations 2 Health News:Labor Board Decision Puts Kaiser Workers' Pay, Healthcare, Pensions in Jeopardy 2 Health News:Criteria based on CT imaging after chemotherapy may help predict survival 2 Health News:ASH to Encourage High School Students to Pursue Biomedical Research Through Special Symposium and Science Curriculum 2 Health News:ASH to Encourage High School Students to Pursue Biomedical Research Through Special Symposium and Science Curriculum 3 Health News:Mexico City to Build World-Class Hub for Medical Research 2

[0] Los Angeles' Kerlan Jobe Orthopaedic Clinic Pays $3 Million to Settle Kickback Allegations [0] Labor Board Decision Puts Kaiser Workers' Pay, Healthcare, Pensions in Jeopardy [0] Criteria based on CT imaging after chemotherapy may help predict survival [1] ASH to Encourage High School Students to Pursue Biomedical Research Through Special Symposium and Science Curriculum [1] Mexico City to Build World-Class Hub for Medical Research

... EPS Growth of 53.3 Percent) - , , - Confirms Dou...reased 2009 Dividend by 11 Percent - , , ABBOTT... announced financial results for the first quarter... above the mid-point of Abbott,s previous first-qu...

...upply today announced that after only 20 months it...will now officially be known as Simplex Healthcare... April 15, 2009 -- Simplex Diabetic Supply today a...ur company has accomplished our initial mission of...

...BRA and Medicare considerations; people with disab...althcare coverage , Belle...rovisions in the 2009 American Recovery and Reinve...ing to Allsup , a leading provider of Social Secu...

...to represent executive board and individual union ...on on recognition of collective bargaining rights ...April 15, 2009 -- Taubman Kimelman & Soroka ,...by Local 2222 of the American Federation of Govern...

... issue of the Journal of Clinical Sleep Medicine ...ing sleep disorders in adults with a traumatic bra...ay result in the objective resolution of the sleep...sleep apnea (OSA), three months of treatment with ...

...arasites in east and west Africa carry different r...tiveness of sulfadoxine as an antimalarial drug ma...ations for the manner in which malaria control cam...ffective than working in isolation in each country...

Abbott Reports 16 Percent Earnings Growth in First Quarter; Confirms Double-Digit Earnings Growth Outlook for 2009 Simplex Diabetic Supply Changes Its Name to Simplex Healthcare Jobless Should Evaluate COBRA, Medicare in Light of 2009 Recovery Act Taubman Kimelman & Soroka Retained by AFGE Local 2222 to Advise in Organizing of New York and New Jersey Transportation Security Officers Treating sleep disorders in people with traumatic brain injury may not eliminate symptoms Discovery of variations in resistance to sulfadoxine across Africa

Innova 3100 Water Bath Shaker

55D Double Platform Shaker 11 x 14

Innova 5000 Muti-Tier Shaker

...up to 16 of AutoGen's tube units to prepare 96 sam...te for bacterial cultures and enzyme reactions, su... simplify your DNA extraction process by preparing...lacing our 6-hole tube units directly onto one of ...

Medicine Products:

Innova 3100 Water Bath Shaker 55D Double Platform Shaker 11 x 14 Innova 5000 Muti-Tier Shaker AutoIncubator 96

( E is right for her. A womanshould not ...)Baraclude (entecavir) Therapy Resulted in Undetectable Levels of,Hepatitis B Virus in Cohort of Patients Who Re-Started Treatment,Health